HIV/AIDS epidemiology, pathogenesis, prevention, and treatment

The HIV-1 pandemic is a complex mix of diverse epidemics within and between countries and regions of the world, and is undoubtedly the defining public-health crisis of our time. Research has deepened our understanding of how the virus replicates, manipulates, and hides in an infected person. Although our understanding of pathogenesis and transmission dynamics has become more nuanced and prevention options have expanded, a cure or protective vaccine remains elusive. Antiretroviral treatment has transformed AIDS from an inevitably fatal condition to a chronic, manageable disease in some settings. This transformation has yet to be realised in those parts of the world that continue to bear a disproportionate burden of new HIV-1 infections and are most affected by increasing morbidity and mortality. This Seminar provides an update on epidemiology, pathogenesis, treatment, and prevention interventions pertinent to HIV-1.

[1]  E. Schouten,et al.  Scaling up antiretroviral therapy in Africa: learning from tuberculosis control programmes--the case of Malawi. , 2005, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[2]  Richard A. Lempicki,et al.  Identification of Dynamically Distinct Subpopulations of T Lymphocytes That Are Differentially Affected by HIV , 2001, The Journal of experimental medicine.

[3]  N. Rollins,et al.  Preventing postnatal transmission of HIV-1 through breast-feeding: modifying infant feeding practices. , 2004, Journal of acquired immune deficiency syndromes.

[4]  R. Osathanondh,et al.  HIV-1 Langerhans' Cell Tropism Associated with Heterosexual Transmission of HIV , 1996, Science.

[5]  G. Garnett,et al.  The Impact of Migration on HIV-1 Transmission in South Africa: A Study of Migrant and Nonmigrant Men and Their Partners , 2003, Sexually transmitted diseases.

[6]  C. M. Owens,et al.  The cytoplasmic body component TRIM5α restricts HIV-1 infection in Old World monkeys , 2004, Nature.

[7]  J. Schwebke Abnormal vaginal flora as a biological risk factor for acquisition of HIV infection and sexually transmitted diseases. , 2005, The Journal of infectious diseases.

[8]  J. Habbema,et al.  Determinants of the impact of sexually transmitted infection treatment on prevention of HIV infection: a synthesis of evidence from the Mwanza, Rakai, and Masaka intervention trials. , 2005, The Journal of infectious diseases.

[9]  L. Ferradini,et al.  Simplifying and adapting antiretroviral treatment in resource-poor settings: a necessary step to scaling-up. , 2004, AIDS.

[10]  John P. Moore,et al.  Inhibiting sexual transmission of HIV-1 infection , 2003, Nature Reviews Microbiology.

[11]  Hui Li,et al.  Nef-Mediated Suppression of T Cell Activation Was Lost in a Lentiviral Lineage that Gave Rise to HIV-1 , 2006, Cell.

[12]  Robin Shattock,et al.  In Vitro and In Vivo: The Story of Nonoxynol 9 , 2005, Journal of acquired immune deficiency syndromes.

[13]  Bernard Branson,et al.  A rapid review of rapid HIV antibody tests , 2006, Current infectious disease reports.

[14]  W. Mcfarland,et al.  Acceptability of Adult Male Circumcision for Sexually Transmitted Disease and HIV Prevention in Zimbabwe , 2005, Sexually transmitted diseases.

[15]  T. Quinn,et al.  HIV/AIDS in Women: An Expanding Epidemic , 2005, Science.

[16]  S. Louisirirotchanakul,et al.  Usage of dried blood spots for molecular diagnosis and monitoring HIV-1 infection. , 2005, Journal of virological methods.

[17]  F. Antunes,et al.  Post-Exposure Prophylaxis of HIV Infection in Healthcare Workers: Recommendations for the European Setting , 2003, European Journal of Epidemiology.

[18]  A. Haase Perils at mucosal front lines for HIV and SIV and their hosts , 2005, Nature Reviews Immunology.

[19]  I. Kleinschmidt,et al.  Young people's sexual health in South Africa: HIV prevalence and sexual behaviors from a nationally representative household survey , 2005, AIDS.

[20]  F. E. McCutchan,et al.  In-Depth Analysis of a Heterosexually Acquired Human Immunodeficiency Virus Type 1 Superinfection: Evolution, Temporal Fluctuation, and Intercompartment Dynamics from the Seronegative Window Period through 30 Months Postinfection , 2005, Journal of Virology.

[21]  B. Rovin,et al.  The Influence of CCL 3 L 1 Gene – Containing Segmental Duplications on HIV-1 / AIDS Susceptibility , 2009 .

[22]  G. Satten,et al.  Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. , 1998, The New England journal of medicine.

[23]  M. Lederman,et al.  HIV long-term non-progressors maintain brisk CD8 T cell responses to other viral antigens , 2002, AIDS.

[24]  A. van der Straten,et al.  Predictors of Diaphragm Use as a Potential Sexually Transmitted Disease/HIV Prevention Method in Zimbabwe , 2005, Sexually transmitted diseases.

[25]  J. T. Boerma,et al.  Community effects on the risk of HIV infection in rural Tanzania , 2002, Sexually transmitted infections.

[26]  Cohen Ms,et al.  Amplified HIV transmission and new approaches to HIV prevention. Editorial commentary. , 2005 .

[27]  S. Nisole,et al.  TRIM family proteins: retroviral restriction and antiviral defence , 2005, Nature Reviews Microbiology.

[28]  D. Jamieson,et al.  Integrating family planning and prevention of mother-to-child HIV transmission in resource-limited settings , 2005, The Lancet.

[29]  J. Weber,et al.  The Development of Vaginal Microbicides for the Prevention of HIV Transmission , 2005, PLoS medicine.

[30]  R. Bosch,et al.  Coaxing HIV-1 from resting CD4 T cells: histone deacetylase inhibition allows latent viral expression , 2004, AIDS.

[31]  D. Richman,et al.  HIV superinfection. , 2005, The Journal of infectious diseases.

[32]  L. Bekker,et al.  Initiating highly active antiretroviral therapy in sub-Saharan Africa: an assessment of the revised World Health Organization scaling-up guidelines , 2004, AIDS.

[33]  Christine Hogan,et al.  Primary HIV-1 Infection Is Associated with Preferential Depletion of CD4+ T Lymphocytes from Effector Sites in the Gastrointestinal Tract , 2004, The Journal of experimental medicine.

[34]  S. Shorte,et al.  CXCR4-Tropic HIV-1 Envelope Glycoprotein Functions as a Viral Chemokine in Unstimulated Primary CD4+ T Lymphocytes1 , 2004, Journal of Immunology.

[35]  M. Emerman,et al.  Ancient Adaptive Evolution of the Primate Antiviral DNA-Editing Enzyme APOBEC3G , 2004, PLoS biology.

[36]  Emmanuel Lagarde,et al.  Randomized, Controlled Intervention Trial of Male Circumcision for Reduction of HIV Infection Risk: The ANRS 1265 Trial , 2005, PLoS medicine.

[37]  P. Bieniasz,et al.  Late budding domains and host proteins in enveloped virus release. , 2006, Virology.

[38]  B. Cullen Role and Mechanism of Action of the APOBEC3 Family of Antiretroviral Resistance Factors , 2006, Journal of Virology.

[39]  K. Mansfield,et al.  Hexon-chimaeric adenovirus serotype 5 vectors circumvent pre-existing anti-vector immunity , 2006, Nature.

[40]  Michelle de Souza,et al.  Bacterial vaginosis and susceptibility to HIV infection in South African women: a nested case-control study. , 2005, The Journal of infectious diseases.

[41]  Xianghui Yu,et al.  Differential Requirement for Conserved Tryptophans in Human Immunodeficiency Virus Type 1 Vif for the Selective Suppression of APOBEC3G and APOBEC3F , 2006, Journal of Virology.

[42]  G. Maartens,et al.  Outcomes after two years of providing antiretroviral treatment in Khayelitsha, South Africa , 2004, AIDS.

[43]  M. Garenne Male Circumcision and HIV Control in Africa , 2006, PLoS medicine.

[44]  P. Kulkarni,et al.  Resistance to HIV-1 infection: lessons learned from studies of highly exposed persistently seronegative (HEPS) individuals. , 2003, AIDS reviews.

[45]  D. Katzenstein,et al.  Breast-milk shedding of drug-resistant HIV-1 subtype C in women exposed to single-dose nevirapine. , 2005, The Journal of infectious diseases.

[46]  Jon Cohen,et al.  Public health. AIDS vaccine trial produces disappointment and confusion. , 2003, Science.

[47]  Reuben S. Harris,et al.  Retroviral restriction by APOBEC proteins , 2004, Nature Reviews Immunology.

[48]  D. Francis,et al.  Candidate HIV/AIDS vaccines: lessons learned from the World's first phase III efficacy trials , 2003, AIDS.

[49]  S. Mallal,et al.  Antiretroviral-therapy-associated lipoatrophy: current status and future directions. , 2005, Sexual health.

[50]  A. Wald,et al.  Once-daily valacyclovir to reduce the risk of transmission of genital herpes. , 2004, The New England journal of medicine.

[51]  M. Neuberger,et al.  In Vitro Deamination of Cytosine to Uracil in Single-stranded DNA by Apolipoprotein B Editing Complex Catalytic Subunit 1 (APOBEC1)* , 2003, Journal of Biological Chemistry.

[52]  A. Winston,et al.  The use of a triple nucleoside‐nucleotide regimen for nonoccupational HIV post‐exposure prophylaxis , 2005, HIV medicine.

[53]  A. Mocroft,et al.  Starting highly active antiretroviral therapy: why, when and response to HAART. , 2004, The Journal of antimicrobial chemotherapy.

[54]  S. A. Abdool Karim,et al.  Seroprevalence of HIV infection in rural South Africa , 1992, AIDS.

[55]  C. Orrell Antiretroviral adherence in a resource-poor setting , 2005, Current HIV/AIDS reports.

[56]  Constance A Nyamukapa,et al.  HIV Decline Associated with Behavior Change in Eastern Zimbabwe , 2006, Science.

[57]  M. Newell,et al.  Exposure to antiretroviral therapy in utero or early life: the health of uninfected children born to HIV-infected women. , 2003, Journal of acquired immune deficiency syndromes.

[58]  J V Giorgi,et al.  Shorter survival in advanced human immunodeficiency virus type 1 infection is more closely associated with T lymphocyte activation than with plasma virus burden or virus chemokine coreceptor usage. , 1999, The Journal of infectious diseases.

[59]  D. Harris,et al.  Alternatives to HIV-1 RNA concentration and CD4 count to predict mortality in HIV-1-infected children in resource-poor settings , 2003, The Lancet.

[60]  Jim Y. Kim,et al.  Scaling-up treatment for HIV/AIDS: lessons learned from multidrug-resistant tuberculosis , 2004, The Lancet.

[61]  Katharina Kober,et al.  Scaling up access to antiretroviral treatment in southern Africa: who will do the job? , 2004, The Lancet.

[62]  M. Tremblay,et al.  Plunder and Stowaways: Incorporation of Cellular Proteins by Enveloped Viruses , 2005, Journal of Virology.

[63]  R. Short,et al.  How does male circumcision protect against HIV infection? , 2000, BMJ : British Medical Journal.

[64]  T. Quinn,et al.  Viral load and heterosexual transmission of human immunodeficiency virus type 1. Rakai Project Study Group. , 2000, The New England journal of medicine.

[65]  Joseph Sodroski,et al.  Specific recognition and accelerated uncoating of retroviral capsids by the TRIM5alpha restriction factor. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[66]  S. Weller,et al.  Condom effectiveness in reducing heterosexual HIV transmission. , 2002, The Cochrane database of systematic reviews.

[67]  A. Telenti,et al.  HIV-1 co/super-infection in intravenous drug users , 2004, AIDS.

[68]  P. Bieniasz,et al.  Role of ESCRT-I in Retroviral Budding , 2003, Journal of Virology.

[69]  James Curran,et al.  Scaling Up Antiretroviral Therapy in Resource-Limited Settings: Treatment Guidelines for a Public Health Approach , 2005 .

[70]  A. Telenti,et al.  Host genetics of HIV-1 susceptibility , 2006 .

[71]  J. Bartlett Dual HIV-1 infection associated with rapid disease progression , 2004 .

[72]  R. Reichman,et al.  APOBEC3G/CEM15 (hA3G) mRNA Levels Associate Inversely with Human Immunodeficiency Virus Viremia , 2005, Journal of Virology.

[73]  S. Eshleman,et al.  Nevirapine resistance after single dose prophylaxis. , 2002, AIDS reviews.

[74]  B. Berkhout,et al.  Triple HIV-1 infection. , 2005, The New England journal of medicine.

[75]  M. Breindl,et al.  Transcriptionally active genome regions are preferred targets for retrovirus integration , 1990, Journal of virology.

[76]  F. Miedema,et al.  T cell dynamics in HIV-1 infection. , 1999, Advances in immunology.

[77]  M. Bachmann Effectiveness and cost effectiveness of early and late prevention of HIV/AIDS progression with antiretrovirals or antibiotics in Southern African adults , 2006, AIDS care.

[78]  N. Low,et al.  HIV and male circumcision--a systematic review with assessment of the quality of studies. , 2005, The Lancet. Infectious diseases.

[79]  D. Ho,et al.  Natural Variation in Vif: Differential Impact on APOBEC3G/3F and a Potential Role in HIV-1 Diversification , 2005, PLoS pathogens.

[80]  Alan S. Perelson,et al.  Turnover Rates of B Cells, T Cells, and NK Cells in Simian Immunodeficiency Virus-Infected and Uninfected Rhesus Macaques1 , 2003, The Journal of Immunology.

[81]  M. Carrington,et al.  Genetics of HIV-1 infection: chemokine receptor CCR5 polymorphism and its consequences. , 1999, Human molecular genetics.

[82]  M. Newell Current issues in the prevention of mother-to-child transmission of HIV-1 infection. , 2006, Transactions of the Royal Society of Tropical Medicine and Hygiene.

[83]  N. Landau,et al.  New insights into the role of Vif in HIV-1 replication. , 2004, AIDS reviews.

[84]  P. Bieniasz Intrinsic immunity: a front-line defense against viral attack , 2004, Nature Immunology.

[85]  D. Ho,et al.  Genotypic and phenotypic characterization of HIV-1 patients with primary infection. , 1993, Science.

[86]  R. Zachariah,et al.  High acceptability of voluntary counselling and HIV‐testing but unacceptable loss to follow up in a prevention of mother‐to‐child HIV transmission programme in rural Malawi: scaling‐up requires a different way of acting , 2005, Tropical medicine & international health : TM & IH.

[87]  K. Hertogs,et al.  Long-cycle structured intermittent versus continuous highly active antiretroviral therapy for the treatment of chronic infection with human immunodeficiency virus: effects on drug toxicity and on immunologic and virologic parameters. , 2003, The Journal of infectious diseases.

[88]  M. Malim,et al.  Cytidine deamination and resistance to retroviral infection: towards a structural understanding of the APOBEC proteins. , 2005, Virology.

[89]  F. Behets,et al.  Desperately seeking targets: the ethics of routine HIV testing in low-income countries. , 2006, Bulletin of the World Health Organization.

[90]  H. Epstein,et al.  Concurrent sexual partnerships help to explain Africa's high HIV prevalence: implications for prevention , 2004, The Lancet.

[91]  R. Doms,et al.  HIV-1 coreceptors and their inhibitors. , 2006, Current topics in microbiology and immunology.

[92]  M. Feinberg,et al.  Prospects for an AIDS vaccine: three big questions, no easy answers. , 2004, The Lancet. Infectious diseases.

[93]  O. Laeyendecker,et al.  Rates of HIV-1 transmission per coital act, by stage of HIV-1 infection, in Rakai, Uganda. , 2005, The Journal of infectious diseases.

[94]  M. Newell,et al.  Efficacy and safety of cesarean delivery for prevention of mother-to-child transmission of HIV-1. , 2005, The Cochrane database of systematic reviews.

[95]  H. Rees,et al.  Effectiveness of COL-1492, a nonoxynol-9 vaginal gel, on HIV-1 transmission in female sex workers: a randomised controlled trial , 2002, The Lancet.

[96]  C. Gilks,et al.  Scaling up treatment--why we can't wait. , 2005, The New England journal of medicine.

[97]  N. Sewankambo,et al.  Population-based study of fertility in women with HIV-1 infection in Uganda , 1998, The Lancet.

[98]  E. Vittinghoff,et al.  Sexual Risk, Nitrite Inhalant Use, and Lack of Circumcision Associated With HIV Seroconversion in Men Who Have Sex With Men in the United States , 2005, Journal of acquired immune deficiency syndromes.

[99]  L. Wain,et al.  Chimpanzee Reservoirs of Pandemic and Nonpandemic HIV-1 , 2006, Science.

[100]  W. Cates Review of Non-hormonal Contraception (Condoms, Intrauterine Devices, Nonoxynol-9 and Combos) on HIV Acquisition , 2005, Journal of acquired immune deficiency syndromes.

[101]  G. Boiteau,et al.  J. Virol. Methods , 1996, Journal of Virological Methods.

[102]  L. Duffy Culture and Context of HIV Prevention in Rural Zimbabwe: The Influence of Gender Inequality , 2005, Journal of transcultural nursing : official journal of the Transcultural Nursing Society.

[103]  A. Kamali,et al.  Migration and HIV‐1 seroprevalence in a rural Ugandan population , 1995, AIDS.

[104]  O. Yang,et al.  Transience of vaccine-induced HIV-1-specific CTL and definition of vaccine "response". , 2006, Vaccine.

[105]  L. John,et al.  Prevention of Mother-to-Child Transmission of HIV Infection , 2005 .

[106]  M. Malim,et al.  Isolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral Vif protein , 2002, Nature.

[107]  Paul Shinn,et al.  A role for LEDGF/p75 in targeting HIV DNA integration , 2005, Nature Medicine.

[108]  P. Musoke,et al.  Persistence of Nevirapine Exposure During the Postpartum Period After Intrapartum Single-Dose Nevirapine in Addition to Zidovudine Prophylaxis for the Prevention of Mother-to-Child Transmission of HIV-1 , 2005, Journal of acquired immune deficiency syndromes.

[109]  J. Montaner,et al.  Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America. , 2003, The New England journal of medicine.

[110]  J. Sodroski,et al.  The HIV-1 envelope glycoproteins: fusogens, antigens, and immunogens. , 1998, Science.

[111]  J. Callen A longitudinal study of human immunodeficiency virus transmission by heterosexual partners: de Vincenzi I for the European Study Group on Heterosexual Transmission of HIV. N Engl J Med 1994;331:341–346 , 1995 .

[112]  Adeeba Kamarulzaman,et al.  AIDS Res Hum Retroviruses , 2006 .

[113]  M. Markowitz,et al.  The gastrointestinal tract is critical to the pathogenesis of acute HIV-1 infection. , 2005, The Journal of allergy and clinical immunology.

[114]  S. Aral,et al.  Measuring outcomes of behavioural interventions for STD/HIV prevention , 1996, International journal of STD & AIDS.

[115]  Q. A. Karim,et al.  The evolving HIV epidemic in South Africa , 2002 .

[116]  G. Garnett,et al.  A Systematic Review of the Epidemiologic Interactions Between Classic Sexually Transmitted Diseases and HIV: How Much Really Is Known? , 2001, Sexually transmitted diseases.

[117]  N. Ford,et al.  Scaling up of highly active antiretroviral therapy in a rural district of Malawi: an effectiveness assessment , 2006, The Lancet.

[118]  O. Shisana,et al.  Correcting gender inequalities is central to controlling HIV/AIDS. , 2004, Bulletin of the World Health Organization.

[119]  J. Schapiro,et al.  Antiretroviral Drug Resistance in Non-Subtype B HIV-1, HIV-2 and Siv , 2004, Antiviral therapy.

[120]  Sebastian Bonhoeffer,et al.  Rapid production and clearance of HIV-1 and hepatitis C virus assessed by large volume plasma apheresis , 1999, The Lancet.

[121]  P S Kim,et al.  Mechanisms of viral membrane fusion and its inhibition. , 2001, Annual review of biochemistry.

[122]  B. Hirschel,et al.  Planned interruptions of anti-HIV treatment. , 2001, The Lancet. Infectious diseases.

[123]  Z. Stein Vaginal microbicides and prevention of HIV infection , 1994, The Lancet.

[124]  D. Burton,et al.  GP120: target for neutralizing HIV-1 antibodies. , 2006, Annual review of immunology.

[125]  M. Malim,et al.  HIV-1 regulatory/accessory genes: keys to unraveling viral and host cell biology. , 1998, Science.

[126]  K. Holmes,et al.  Advances in multilevel approaches to understanding the epidemiology and prevention of sexually transmitted infections and HIV: an overview. , 2005, The Journal of infectious diseases.

[127]  L. Calza,et al.  Dyslipidaemia associated with antiretroviral therapy in HIV-infected patients. , 2003, The Journal of antimicrobial chemotherapy.

[128]  F. Dabis,et al.  Low risk of nevirapine resistance mutations in the prevention of mother-to-child transmission of HIV-1: Agence Nationale de Recherches sur le SIDA Ditrame Plus, Abidjan, Cote d'Ivoire. , 2006, The Journal of infectious diseases.

[129]  S. Wain-Hobson,et al.  The HIV-1 clade C promoter is particularly well adapted to replication in the gut in primary infection , 2006, AIDS.

[130]  D. Pérez-Caballero,et al.  Restriction of Human Immunodeficiency Virus Type 1 by TRIM-CypA Occurs with Rapid Kinetics and Independently of Cytoplasmic Bodies, Ubiquitin, and Proteasome Activity , 2005, Journal of Virology.

[131]  T. Quinn,et al.  The Effects of Herpes Simplex Virus-2 on HIV-1 Acquisition and Transmission: A Review of Two Overlapping Epidemics , 2004, Journal of acquired immune deficiency syndromes.

[132]  D. Ho,et al.  HIV-1 dynamics in vivo: implications for therapy , 2003, Nature Reviews Microbiology.

[133]  Cheryl Jennings,et al.  Depletion of latent HIV-1 infection in vivo: a proof-of-concept study , 2005, The Lancet.

[134]  F. Barré-Sinoussi HIV as the cause of AIDS , 1996, The Lancet.

[135]  J. Bremer,et al.  Comparison of Two Human Immunodeficiency Virus (HIV) RNA Surrogate Assays to the Standard HIV RNA Assay , 2005, Journal of Clinical Microbiology.

[136]  Bhavna Chohan,et al.  Evidence for Frequent Reinfection with Human Immunodeficiency Virus Type 1 of a Different Subtype , 2005, Journal of Virology.

[137]  N. Saksena,et al.  HIV-1 co-infection, superinfection and recombination. , 2004, Sexual health.

[138]  Cott,et al.  ANTIRETROVIRAL THERAPY DURING PREGNANCY AND THE RISK OF AN ADVERSE OUTCOME , 2002 .

[139]  D. Trono,et al.  Lentiviral vectors and antiretroviral intrinsic immunity. , 2005, Human gene therapy.

[140]  B. Korber,et al.  Evolutionary and immunological implications of contemporary HIV-1 variation. , 2001, British medical bulletin.

[141]  R. Hayes,et al.  Control of sexually transmitted diseases for HIV-1 prevention: understanding the implications of the Mwanza and Rakai trials , 2000, The Lancet.

[142]  H. Gershengorn,et al.  A tale of two futures: HIV and antiretroviral therapy in San Francisco. , 2000, Science.

[143]  R. Hogg,et al.  Improved survival among HIV-infected individuals following initiation of antiretroviral therapy. , 1998, JAMA.

[144]  B. Masquelier,et al.  Characterization of nevirapine (NVP) resistance mutations and HIV type 1 subtype in women from Abidjan (Côte d'Ivoire) after NVP single-dose prophylaxis of HIV type 1 mother-to-child transmission. , 2005, AIDS research and human retroviruses.

[145]  S. Deeks,et al.  Treatment of antiretroviral-drug-resistant HIV-1 infection , 2003, The Lancet.

[146]  J. Margolick,et al.  Evaluation of a Low-Cost Method, the Guava EasyCD4 Assay, to Enumerate CD4-Positive Lymphocyte Counts in HIV-Infected Patients in the United States and Uganda , 2006, Journal of acquired immune deficiency syndromes.

[147]  N. Sewankambo,et al.  Increased risk of incident HIV during pregnancy in Rakai, Uganda: a prospective study , 2005, The Lancet.

[148]  J. Mellors,et al.  Persistence of nevirapine-resistant HIV-1 in women after single-dose nevirapine therapy for prevention of maternal-to-fetal HIV-1 transmission. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[149]  R. Bailey,et al.  Susceptibility to human immunodeficiency virus-1 infection of human foreskin and cervical tissue grown in explant culture. , 2002, The American journal of pathology.

[150]  Wesley I. Sundquist,et al.  Tsg101 and the Vacuolar Protein Sorting Pathway Are Essential for HIV-1 Budding , 2001, Cell.

[151]  A. Woolfson,et al.  Long-term, controlled release of the HIV microbicide TMC120 from silicone elastomer vaginal rings. , 2005, The Journal of antimicrobial chemotherapy.

[152]  J. Blackard,et al.  Human immunodeficiency virus superinfection and recombination: current state of knowledge and potential clinical consequences. , 2002, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[153]  N. Low,et al.  Male circumcision for prevention of heterosexual acquisition of HIV in men. , 2003, The Cochrane database of systematic reviews.

[154]  H. Weiss,et al.  Longitudinal Assessment of HIV-1 and HSV-2 Shedding in the Genital Tract of West African Women , 2005, Journal of acquired immune deficiency syndromes.

[155]  R. Walensky,et al.  Two drugs or three? Balancing efficacy, toxicity, and resistance in postexposure prophylaxis for occupational exposure to HIV. , 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[156]  Christine Katlama,et al.  Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia. , 2003, The New England journal of medicine.

[157]  R. König,et al.  Complementary function of the two catalytic domains of APOBEC3G. , 2005, Virology.

[158]  F. Förster,et al.  The mechanism of HIV-1 core assembly: insights from three-dimensional reconstructions of authentic virions. , 2006, Structure.

[159]  W. Greene,et al.  Cellular APOBEC3G restricts HIV-1 infection in resting CD4+ T cells , 2005, Nature.

[160]  Adriano Lazzarin,et al.  The Efficiency of Male‐to Female and Female‐to‐Male Sexual Transmission of the Human Immunodeficiency Virus: A Study of 730 Stable Couples , 1994, Epidemiology.

[161]  R. Connor,et al.  Change in Coreceptor Use Correlates with Disease Progression in HIV-1–Infected Individuals , 1997, The Journal of experimental medicine.

[162]  N. Leidy,et al.  Effect of long-cycle structured intermittent versus continuous HAART on quality of life in patients with chronic HIV infection , 2006, AIDS.

[163]  K. Mayer,et al.  Microbicides to prevent HIV transmission: overcoming obstacles to chemical barrier protection. , 2006, The Journal of infectious diseases.

[164]  P. Roques,et al.  Phenotypic Susceptibility to Nonnucleoside Inhibitors of Virion-Associated Reverse Transcriptase From Different HIV Types and Groups , 2004, Journal of acquired immune deficiency syndromes.

[165]  Paul Shinn,et al.  HIV-1 Integration in the Human Genome Favors Active Genes and Local Hotspots , 2002, Cell.

[166]  Lynn Morris,et al.  Impact of HIV-1 Subtype and Antiretroviral Therapy on Protease and Reverse Transcriptase Genotype: Results of a Global Collaboration , 2005, PLoS medicine.

[167]  P. Klotman,et al.  Antiretroviral therapy and the kidney: balancing benefit and risk in patients with HIV infection , 2006, Expert opinion on drug safety.

[168]  A. Engelman,et al.  A tripartite DNA-binding element, comprised of the nuclear localization signal and two AT-hook motifs, mediates the association of LEDGF/p75 with chromatin in vivo , 2006, Nucleic acids research.

[169]  I. Dunham,et al.  An anthropoid-specific locus of orphan C to U RNA-editing enzymes on chromosome 22. , 2002, Genomics.

[170]  R. Bosch,et al.  The Development and Utility of a Clinical Algorithm to Predict Early HIV-1 Infection , 2005, Journal of acquired immune deficiency syndromes.

[171]  P. Foster,et al.  The viral manipulation of the host cellular and immune environments to enhance propagation and survival: a focus on RNA viruses , 2002, Journal of leukocyte biology.

[172]  S. Weller,et al.  Condom effectiveness in reducing heterosexual HIV transmission. , 2002, The Cochrane database of systematic reviews.

[173]  J. Nkengasong,et al.  Integrating Prevention of Mother-to-Child HIV Transmission Into Routine Antenatal Care: The Key to Program Expansion in Cameroon , 2005, Journal of acquired immune deficiency syndromes.

[174]  F. Bushman,et al.  Retroviral DNA Integration: ASLV, HIV, and MLV Show Distinct Target Site Preferences , 2004, PLoS biology.

[175]  I. de Vincenzi,et al.  A Longitudinal Study of Human Immunodeficiency Virus Transmission by Heterosexual Partners , 1994 .

[176]  R. Miksad,et al.  From treatment to prevention: The interplay between HIV/AIDS treatment availability and HIV/AIDS prevention programming in Khayelitsha, South Africa , 2005, Journal of Urban Health.

[177]  M. Magoni,et al.  Mode of infant feeding and HIV infection in children in a program for prevention of mother-to-child transmission in Uganda , 2005, AIDS.

[178]  Myron S. Cohen,et al.  The role of sexually transmitted diseases in HIV transmission , 2004, Nature Reviews Microbiology.

[179]  Christopher D Pilcher,et al.  Amplified HIV transmission and new approaches to HIV prevention. , 2005, The Journal of infectious diseases.

[180]  R. Hayes,et al.  Understanding HIV Epidemic Trends in Africa , 2006, Science.

[181]  M. Vray,et al.  Plasma virion reverse transcriptase activity and heat dissociation-boosted p24 assay for HIV load in Burkina Faso, West Africa , 2005, AIDS.

[182]  P. Price,et al.  Immune restoration disease after antiretroviral therapy , 2004, AIDS.

[183]  A. Wensing,et al.  Worldwide transmission of drug-resistant HIV. , 2003, AIDS reviews.

[184]  Richard A Lempicki,et al.  HIV envelope induces a cascade of cell signals in non-proliferating target cells that favor virus replication , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[185]  N. Hosken Development of a therapeutic vaccine for HSV-2. , 2005, Vaccine.

[186]  H. Doerr,et al.  Comparative evaluation of the Cobas Amplicor HIV-1 Monitor Ultrasensitive Test, the new Cobas AmpliPrep/Cobas Amplicor HIV-1 Monitor Ultrasensitive Test and the Versant HIV RNA 3.0 assays for quantitation of HIV-1 RNA in plasma samples. , 2005, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

[187]  D. Hoover,et al.  Quantitative Analysis of HIV-1 Variants With the K103N Resistance Mutation After Single-Dose Nevirapine in Women With HIV-1 Subtypes A, C, and D , 2006, Journal of acquired immune deficiency syndromes.

[188]  N. Davidson,et al.  APOBEC3F and APOBEC3G mRNA Levels Do Not Correlate with Human Immunodeficiency Virus Type 1 Plasma Viremia or CD4+ T-Cell Count , 2006, Journal of Virology.

[189]  P. Kissinger,et al.  Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. , 1998, The New England journal of medicine.

[190]  Alan S. Perelson,et al.  Increased Turnover of T Lymphocytes in HIV-1 Infection and Its Reduction by Antiretroviral Therapy , 2001, The Journal of experimental medicine.

[191]  U. Abbas,et al.  Interruption of antiretroviral therapy to augment immune control of chronic HIV-1 infection: Risk without reward , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[192]  JD Lundgren,et al.  Changing patterns of mortality across Europe in patients infected with HIV-1 , 1998, The Lancet.

[193]  M. Thomson,et al.  Molecular epidemiology of HIV-1 variants in the global AIDS pandemic: an update. , 2005, AIDS reviews.

[194]  Tara L. Kieffer,et al.  G→A Hypermutation in Protease and Reverse Transcriptase Regions of Human Immunodeficiency Virus Type 1 Residing in Resting CD4+ T Cells In Vivo , 2005, Journal of Virology.

[195]  A. Wald,et al.  Valacyclovir and acyclovir for suppression of shedding of herpes simplex virus in the genital tract. , 2004, The Journal of infectious diseases.

[196]  D. Ho,et al.  The HIV-1 Vaccine Race , 2002, Cell.

[197]  John T McDevitt,et al.  A Microchip CD4 Counting Method for HIV Monitoring in Resource-Poor Settings , 2005, PLoS medicine.

[198]  W. Miller,et al.  Trichomoniasis in men and HIV infection: data from 2 outpatient clinics at Lilongwe Central Hospital, Malawi. , 2004, The Journal of infectious diseases.

[199]  P. Bieniasz,et al.  HIV-1 and Ebola virus encode small peptide motifs that recruit Tsg101 to sites of particle assembly to facilitate egress , 2001, Nature Medicine.

[200]  J. McIntyre Strategies to prevent mother-to-child transmission of HIV , 2006, Current opinion in infectious diseases.